E Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History

E Fund Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$318K	Sell	86,519 -25,431	-23%	-$84.7K	0.01%	370
2026 Q1	$344K	Buy	+111,950	New	+$433K	0.01%	359
2025 Q2	$201K	Sell	39,653 -16,272	-29%	-$79.9K	0.01%	362
2025 Q1	$296K	Buy	55,925 +13,604	+32%	+$99.2K	0.01%	317
2024 Q4	$286K	Sell	42,321 -1,097	-3%	-$7.38K	0.01%	324
2024 Q3	$286K	Buy	43,418 +19,253	+80%	+$138K	0.01%	266
2024 Q2	$181K	Sell	24,165 -14,562	-38%	-$127K	0.01%	296
2024 Q1	$386K	Sell	38,727 -15,367	-28%	-$171K	0.02%	229
2023 Q4	$533K	Sell	54,094 -2,638	-5%	-$18.8K	0.03%	149
2023 Q3	$434K	Buy	56,732 +39,503	+229%	+$394K	0.03%	148
2023 Q2	$129K	Sell	17,229 -4,188	-20%	-$29.3K	0.01%	293
2023 Q1	$143K	Sell	21,417 -5,694	-21%	-$45.2K	0.01%	313
2022 Q4	$209K	Buy	27,111 +15,252	+129%	+$150K	0.02%	297
2022 Q3	$126K	Buy	+11,859	New	+$120K	0.01%	323

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

E Fund Management's RXRX Position: Q2 2026 in Review

E Fund Management reduced its Recursion Pharmaceuticals (RXRX) stake by 23% in Q2 2026, selling an estimated $84.7K and leaving 86,519 shares worth $318K. The position accounts for 0.01% of the portfolio, ranked #370.

E Fund Management first reported a position in RXRX in Q3 2022 and has held it in 14 quarters since. The position peaked at $533K in Q4 2023. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

E Fund Management held 86,519 shares of Recursion Pharmaceuticals worth $318K as of Q2 2026.
E Fund Management sold 25,431 Recursion Pharmaceuticals shares in Q2 2026, an estimated $84.7K.
Recursion Pharmaceuticals made up 0.01% of E Fund Management's portfolio in Q2 2026, its #370 holding.
E Fund Management first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 14 quarters since.
E Fund Management's Recursion Pharmaceuticals position peaked at $533K in Q4 2023.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.